https://doi.org/10.4081/ecj.2024.12463
Multimarkers approach in chest pain management in Emergency department: a focus on the prognostic role of sST2 and suPAR
Submitted: 8 March 2024
Accepted: 4 June 2024
Published: 18 June 2024
Accepted: 4 June 2024
Abstract Views: 370
PDF: 301
Supplementary Materials: 153
Supplementary Materials: 153
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Chest pain is one of the most prevalent causes of Emergency Department (ED) admission and could be a presenting symptom of Acute Coronary Syndrome (ACS). The aim of this review was to provide an overview of the research about troponin and its limitations and new biomarkers used in patients with cardiovascular diseases, with a special focus on soluble Suppression of Tumorigenicity 2 (sST2) and Soluble Urokinase Plasminogen Activator Receptor (suPAR). In January 2024, a PubMed and Reviews in Cardiovascular Medicine (RCM) search was carried out to identify all relevant papers in the past five years. 80 articles were included in the final review. ssT2 and suPAR are involved in both acute and chronic cardiovascular disease and can predict the risk of adverse events. sST2 and suPAR are promising biomarkers that, in combination with troponin, could help in the management of patients with chest pain in the ED. Further studies are needed to validate their role in management of ACS in this specific setting.
Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J 2022;43:716-99. Erratum in: Eur Heart J 2022;43:799.
DOI: https://doi.org/10.1093/eurheartj/ehac064
Piccioni A, Valletta F, Zanza C, et al. Novel biomarkers to assess the risk for acute coronary syndrome:beyond troponins. Internal Emerg Med 2020;15:1193–9.
DOI: https://doi.org/10.1007/s11739-020-02422-z
Rehan ST, Hussain Hu, Ali E, et al. Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta analysis. Medicine 2023;102:45.
DOI: https://doi.org/10.1097/MD.0000000000035718
Yang L, Yaqun D, Yinjie Z, et al. Prognostic value of soluble urokinase-type plasminogen activator receptor in coronary artery disease: A meta-analysis.Eur J Clin Invest 2022;52:e13867.
DOI: https://doi.org/10.1111/eci.13867
Holstein RM, Mäkinen MT, Castrén MK, Kaartinen JM. Utilization of prognostic biomarker soluble urokinase plasminogen activator receptor in the emergency department: a tool for safe and more efficient decision-making. Biomarker Insights 2022;17: 1–7.
DOI: https://doi.org/10.1177/11772719221081789
Holstei RM, Seppälä S, Kaartinen J, et al. Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department (Ed): a tool for the assessment of elderly patients. J Clin Med 2022;11:3283.
DOI: https://doi.org/10.3390/jcm11123283
Lazar DR, Lazar FL, Homorodean C, et al. High-sensitivity troponin: a review on characteristics, assessment, and clinical implications. Hindawi Disease Markers 2022;9713326.
DOI: https://doi.org/10.1155/2022/9713326
Boone S, Peacock WF. Contemporary biomarker strategies for patients with chest pain. Rev Cardiovasc Med 2022;23:157.
DOI: https://doi.org/10.31083/j.rcm2305157
Chuang AM, Nguyen MT, Kung WM, et al. High-sensitivity troponin in chronic kidney disease: Considerations in myocardial infarction and beyond. Rev Cardio-vasc Med 2020;21:191–203.
DOI: https://doi.org/10.31083/j.rcm.2020.02.17
Long B, Long DA, Tannenbaum L, Koyfman A. An emergency medicine approach to troponin elevation due to causes other than occlusion myocardial infarction. Am J Emerg Med 2020;38:998-1006.
DOI: https://doi.org/10.1016/j.ajem.2019.12.007
Januzzi JL, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol 2019;73:1059–77.
DOI: https://doi.org/10.1016/j.jacc.2018.12.046
Januzzi JL, McCarthy CP. Cardiac troponin and the true false positive. JACC: Case Reports 2020;2:461–463.
DOI: https://doi.org/10.1016/j.jaccas.2020.01.012
Sandoval Y, Apple FS, Mahle SA, et al. High-sensitivity cardiac troponin and the 2021AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guidelines for the evaluation and diagnosis of acute chest pain. Circulation 2022;146:569–81.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.059678
Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2023;44;3720–826.
Chesnaye NC, Szummer K, Bárány P, et al. Association between renal function and troponin t over time in stable chronic kidney disease patients. J Am Heart Assoc 2019;8:e013091.
DOI: https://doi.org/10.1093/ndt/gfz106.FP411
Bhatia PM, Daniels LB. Highly sensitive cardiac troponins: the evidence behind sex‐specific cutoffs. J Am Heart Assoc 2020;9:e015272.
DOI: https://doi.org/10.1161/JAHA.119.015272
Karády J, Mayrhofer T, Ferencik M, et al. Discordance of high-sensitivity troponin assays in patients with suspected acute coronary syndromes. J Am Coll Cardiol 2021;77:1487–99.
DOI: https://doi.org/10.1016/j.jacc.2021.01.046
U.S. Food and Drug Administration (FDA) safety communication. Biotin Interference with Troponin Lab Tests - Assays Subject to Biotin Interference. 2019. Available at: https: //www.fda.gov/medical-devices/in-vitro-diagnostics/biotin-interference-troponin-lab-tests-assays-subject-biotin-interference
Mumma B, Diercks D, Twerenbold R, et al. Clinical risk assessment of biotin interference with a high-sensitivity cardiac troponin T assay. Clin Chem Lab Med 2020;58:1931–40.
DOI: https://doi.org/10.1515/cclm-2019-0962
Santos LG, Carvalho RR, Sá FM, et al. Circulating heterophile antibodies causing cardiac troponin elevation: an unusual differential diagnosis of myocardial disease. J Am Coll Cardiol Case Rep 2020;2:456–60.
DOI: https://doi.org/10.1016/j.jaccas.2020.01.011
Dudek M, Kałużna-Oleksy M, Migaj J, Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med 2020;29:1205–10.
DOI: https://doi.org/10.17219/acem/126049
Aleksova A, Paldino A, Beltrami AP, et al. Cardiac biomarkers in the emergency department: the role of soluble ST2 (sST2) in acute heart failure and acute coronary syndrome—there is meat on the bone. J Clin Med 2019;8:270.
DOI: https://doi.org/10.3390/jcm8020270
Liu R, Liu L, Wei C, Li D. IL-33/ST2 immunobiology in coronary artery disease: A systematic review and meta-analysis. Front Cardiovasc Med 2022;9:990007.
DOI: https://doi.org/10.3389/fcvm.2022.990007
Liu L, Li S, Ding X, et al. Dynamic changes in soluble suppression of tumorigenicity 2 levels predict major adverse cardiovascular events in patients with ST‐segment elevation myocardial infarction. Pol Arch Intern Med 2022;132:16317.
DOI: https://doi.org/10.20452/pamw.16317
Sun Y, Pavey H, Wilkinson I, Fisk M. Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis. PLoS ONE 2021;16:e0259026.
DOI: https://doi.org/10.1371/journal.pone.0259026
Pascual-Figal DA, Bayes-Genis A, Asensio-Lopez MC, et al. The interleukin-1 axis and risk of death in patients with acutely decompensated heart failure. JACC 2019;73:1016-25
DOI: https://doi.org/10.1016/j.jacc.2018.11.054
Meijers WC, Bayes-Genis A, MebazaA, et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Failure 2021;23:1610–32.
DOI: https://doi.org/10.1002/ejhf.2346
Aimo A, Januzzi JL, Bayes-Genis A, et al. Clinical and Prognostic Significance of sST2 in Heart Failure. JACC 2019;74:2193-203.
DOI: https://doi.org/10.1016/j.jacc.2019.08.1039
Ip C, Luk KS, Yuen VLC, et al. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis. IJC Heart & Vasculature 2021;37:100887.
DOI: https://doi.org/10.1016/j.ijcha.2021.100887
Zhang J, Chen Z, Ma M, He Y. Soluble ST2 in coronary artery disease: Clinical biomarkers and treatment guidance. Front Cardiovasc Med 2022;9:924461.
DOI: https://doi.org/10.3389/fcvm.2022.924461
Clemente G, Soldano JS, Tuttolomondo A. Heart failure: is there an ideal biomarker? Rev Cardiovasc Med 2023;24:310.
DOI: https://doi.org/10.31083/j.rcm2411310
Wang Z, Pan X, Xu H, et al. Serum soluble ST2 is a valuable prognostic biomarker in patients with acute heart failure. Front Cardiovasc Med 2022;9:812654.
DOI: https://doi.org/10.3389/fcvm.2022.812654
Rezar R, Paar V, Seelmaier C, et al. Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study. Sci Rep 2021;11:21756.
DOI: https://doi.org/10.1038/s41598-021-01389-x
Huet F, Dupuy AM, Duflos C, et al. Soluble urokinase-type plasminogen activator receptor strongly predicts global mortality in acute heart failure patients: insight from the STADE-HF registry”. Future Sci OA 2021;FSO697.
DOI: https://doi.org/10.2144/fsoa-2020-0197
Huet F, Nicoleau J, Dupuy AM, et al. STADE-HF (sST2As a help for management of HF): a pilot study. ESC Heart Failure 2020;7:774–8.
DOI: https://doi.org/10.1002/ehf2.12663
Berezin AE, Berezin AA. Biomarkers in heart failure: from research to clinical practice. Ann Lab Med 2023;43:225-36.
DOI: https://doi.org/10.3343/alm.2023.43.3.225
Timothy SD, Hartopo AB, Anggraeni VY, Makrufardi F. Association of soluble ST2 and infarct location within 12–24 h in STEMI: A cross-sectional study. Ann Med Surgery 2021;70:102844.
DOI: https://doi.org/10.1016/j.amsu.2021.102844
Zhang Y, Fan Z, Liu H, et al. Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis. Coron Artery Dis 2020;31:628-35.
DOI: https://doi.org/10.1097/MCA.0000000000000851
Luo G, Qian Y, Sheng X, et al. Elevated serum levels of soluble ST2 are associated with plaque vulnerability in patients with non-ST-elevation acute coronary syndrome. Front Cardiovasc Med 2021;8:688522.
DOI: https://doi.org/10.3389/fcvm.2021.688522
Van den Berg VJ, Vroegindewey MM, Umans VA, et al. Persistently elevated levels of sST2 after acute coronary syndrome are associated with recurrent cardiac events. Biomarkers 2022;27:264-9.
DOI: https://doi.org/10.1080/1354750X.2022.2032350
Liu N, Hang T, Gao X, et al. The association between soluble suppression of tumorigenicity-2 and long term prognosis in patients with coronary artery disease: A meta-analysis. PLoS ONE 2020;15:e0238775.
DOI: https://doi.org/10.1371/journal.pone.0238775
Kim HL, Lee JP, Wong N, et al. Prognostic value of serum soluble ST2 in stable coronary artery disease: a prospective observational study. Sci Rep 2021;11:15203.
DOI: https://doi.org/10.1038/s41598-021-94714-3
Chen D, Untaru R, Stavropoulou G, et al. Elevated soluble suppressor of tumorigenicity 2 predict hospital admissions due to major adverse cardiovascular events (MACE). J Clin Med 2023;12:2790.
DOI: https://doi.org/10.3390/jcm12082790
Velissaris D, Zareifopoulos N, Koniari I, et al. Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease. J Clin Med Res 2021;13:133-42.
Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol 2021;12:780641.
DOI: https://doi.org/10.3389/fimmu.2021.780641
Goodchild TT, Li Z, Lefer DJ. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease. J Clin Invest 2022;132:e165868.
DOI: https://doi.org/10.1172/JCI165868
Pruc M, Jannasz I, Swieczkowski D, et al. Diagnostic value of soluble urokinase-type plasminogen activator receptor in patients with acute coronary syndrome: A systematic review and meta-analysis. Cardiol J 2023;30:335-6.
DOI: https://doi.org/10.5603/cj.96228
Velissaris D, Zareifopoulos N, Karamouzos V, et al. Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update. Caspian J Intern Med 2022;13:650-65.
Wohlwend NF, Grossmann K, Aeschbacher S, et al. The association of suPAR with cardiovascular risk factors in young and healthy adults. Diagnostics 2023;13:2938.
DOI: https://doi.org/10.3390/diagnostics13182938
Hindy G, Tyrrell DJ, Vasbinder A, et al. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J Clin Invest 2022;132:e158788.
DOI: https://doi.org/10.1172/JCI158788
Sörensen NA, Nikorowitsch J, Neumann JT, et al. Predictive value of soluble urokinase‐type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. Clin Res Cardiol 2019;108:1386-93.
DOI: https://doi.org/10.1007/s00392-019-01475-1
Chenevier-Gobeaux C, Lemarechal H, Doumenc B, et al. Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of acute coronary syndrome. Clin Biochem 2021;92:19-24.
DOI: https://doi.org/10.1016/j.clinbiochem.2021.02.009
Santeri S, Andersen AP, Nyyssönen K, et al. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. BMC Emerg Med 2021;21:149.
DOI: https://doi.org/10.1186/s12873-021-00544-x
Velissaris D, Zareifopoulosb N, Koniaric I, et al. Soluble urokinase plasminogen activator receptor as a diagnostic and prognostic biomarker in cardiac disease. J Clin Med Res 2021;13:133-42.
DOI: https://doi.org/10.14740/jocmr4459
Bengaard AK, Versen E, Kallemose T, et al. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department. Br J Clin Pharmacol 2022;88:1679-90.
DOI: https://doi.org/10.1111/bcp.14982
Al-Badri A, Tahhan AS, Sabbak N, et al. Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. J Am Heart Assoc 2020;9:e015515.
DOI: https://doi.org/10.1161/JAHA.119.015515
Frarya CE, Biering-Sørensenc T, Nochiokad K, et al. Sex- and age-related differences in the predictive capability of circulating biomarkers: from the MONICA 10 cohort. Scand Cardiovasc J 2021;55:65–72.
DOI: https://doi.org/10.1080/14017431.2020.1853217
Hodges G, Lyngbæk S, Selmer C, et al. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease. Scand Cardiovasc J 2020;54:339–45.
DOI: https://doi.org/10.1080/14017431.2020.1762917
Sarlo F, Urbani A, Baroni S. Urokinase-type plasminogen activator soluble receptor (suPAR) assay in clinical routine: evaluation one year after its introduction in the high automation corelab of the A. Gemelli hospital. Clin Chem Lab Med 2023;61:e33–5.
DOI: https://doi.org/10.1515/cclm-2022-0686
Abdelmageed M, Güzelgül F. Copeptin: Up-to-date diagnostic and prognostic role highlight. Anal Biochem 2023;15:115181.
DOI: https://doi.org/10.1016/j.ab.2023.115181
Mu D, Zhong J, Li L, et al. Copeptin with high-sensitivity cardiac troponin to rule out non-ST-elevation myocardial infarction early on: A systematic review and meta-analysis. Clin Biochem 2023;112:24-32.
DOI: https://doi.org/10.1016/j.clinbiochem.2022.11.009
Berezin AE, Berezin AA. Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers. Disease Markers Volume 2020;121580.
DOI: https://doi.org/10.1155/2020/1215802
Katsioupa M, Kourampi I, Oikonomou E, et al. Novel biomarkers and their role in the diagnosis and prognosis of acute coronary syndrome. Life 2023;13:1992.
DOI: https://doi.org/10.3390/life13101992
Ion A, Stafie C, Mitu O, et al. Biomarkers utility: at the borderline between cardiology and neurology. J Cardiovasc Dev Dis 2021;8:139.
DOI: https://doi.org/10.3390/jcdd8110139
Maisel A, Mueller C, Neath SX, et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). J Am Coll Cardiol 2013;62:150-60.
DOI: https://doi.org/10.1016/j.jacc.2013.04.011
Jeong JH, Seo YH, Ahn JY, et al. Performance of copeptin for early diagnosis of acute myocardial infarction in an emergency department setting. Ann Lab Med 2020;40:7-14.
DOI: https://doi.org/10.3343/alm.2020.40.1.7
Waldsperger H, Biener M, Stoyanov KM, et al. Prognostic value of elevated copeptin and high-sensitivity cardiac troponin t in patients with and without acute coronary syndrome: the ConTrACS Study. J Clin Med 2020;9:3627.
DOI: https://doi.org/10.3390/jcm9113627
Mueller-Hennessen M, Lindahl B, Giannitsis E, et al. Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. Int J Cardiol 2019;276:261-7
DOI: https://doi.org/10.1016/j.ijcard.2018.10.084
Giannitsis E, Slagman A, Hamm CW, et al. Copeptin combined with either non-high sensitivity or high sensitivity cardiac troponin for instant rule-out of suspected non-ST segment elevation myocardial infarction. Biomarkers 2020;25:649-58.
DOI: https://doi.org/10.1080/1354750X.2020.1833084
Lattuca B, Sy V, Nguyen LS, et al. Copeptin as a prognostic biomarker in acute myocardial infarction. Int J Cardiol 2019;274:337-41.
DOI: https://doi.org/10.1016/j.ijcard.2018.09.022
Ahmed TAN, Johny JS, Abdel-Malek MY, Fouad DA. The additive value of copeptin for early diagnosis and prognosis of acute coronary syndromes. Am J Emerg Med 2021;50:413-21
DOI: https://doi.org/10.1016/j.ajem.2021.08.069
Szarpak L, Lapinski M, Gasecka A, et al. Performance of copeptin for early diagnosis of acute coronary syndromes: a systematic review and meta-analysis of 14,139 patients. J Cardiovasc Dev Dis 2021;9:6.
DOI: https://doi.org/10.3390/jcdd9010006
Pedersen CK, Stengaard C, Bøtker MT, et al. Accelerated -Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study. Eur Heart J 2023;44:3875-88.
DOI: https://doi.org/10.1093/eurheartj/ehad447
Xue S, Zhu W, Liu D, et al. Circulating miR-26a-1, miR-146a and miR199a-1 are potential candidate biomarkers for acute myocardial infrction. Molec Med 2019;25:18.
DOI: https://doi.org/10.1186/s10020-019-0086-1
Topf A, Mirna M, Paar V, et al. The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome. Clin Res Cardiol 2022;111:197–206.
DOI: https://doi.org/10.1007/s00392-021-01956-2
Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews 2022;27:625–43.
DOI: https://doi.org/10.1007/s10741-021-10105-w
Paul S, Harshaw-Ellis K. Evolving use of biomarkers in the management of heart failure. Cardiol Rev 2019;27:153–9.
DOI: https://doi.org/10.1097/CRD.0000000000000224
Idzikowska K, Kacprzak M, Zielinska M. The prognostic value of cardiac biomarkers in patients with acute myocardial infarction during and after hospitalization. Rev Cardiovasc Med 2022;23:320.
DOI: https://doi.org/10.31083/j.rcm2309320
Topf A, Mirna M, Bacher N, et al. Analysis of selected cardiovascular biomarkers in takotsubo cardiomyopathy and the most frequent cardiomyopathies. Front Cardiovasc Med 2021;8:700169.
DOI: https://doi.org/10.3389/fcvm.2021.700169
Stojanovic D, Mitic V, Stojanovic M, et al. The discriminatory ability of renalase and biomarkers of cardiac remodeling for the prediction of ischemia in chronic heart failure patients with the regard to the ejection fraction. Front Cardiovasc Med 2021;8:691513.
DOI: https://doi.org/10.3389/fcvm.2021.691513
How to Cite
Piccioni, A., Baroni, S., Scatà, L. A., Scaccia, M., Candela, M., Bronzino, A., Sarlo , F., Savioli, G., Candelli, M., Covino, M., Gasbarrini, A., & Franceschi, F. (2024). Multimarkers approach in chest pain management in Emergency department: a focus on the prognostic role of sST2 and suPAR . Emergency Care Journal, 20(2). https://doi.org/10.4081/ecj.2024.12463
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
